Systematix Q2 returns to profit, but H1 PBT falls 57%

Systematix Group returned to a consolidated pre-tax profit of Rs 17.19 crore in Q2 FY27 ended September 30, 2026, after a Rs 3.08 crore loss in Q1, but H1 FY27 pre-tax profit fell 57% year on year to Rs 14.11 crore. Management attributed near-term profitability pressure to investment in its private-wealth platform.

Did Systematix return to profit in Q2 FY27?

Yes, Systematix returned to consolidated profit in Q2 FY27, with statutory pre-tax profit of Rs 17.19 crore and profit after tax of Rs 13.13 crore. This followed a pre-tax loss of Rs 3.08 crore and an after-tax loss of Rs 4.89 crore in Q1 FY27, according to the unaudited consolidated results for the quarter ended September 30, 2026.

The sequential recovery came as total income from operations rose to Rs 57.81 crore in Q2 FY27 from Rs 56.26 crore in Q1 FY27. On the presentation's adjusted basis, under which share-trading revenue is recorded as net profit or loss earned, revenue from operations more than doubled to Rs 56.04 crore from Rs 28.02 crore.

Systematix did not exceed its prior-year quarterly profit despite the Q1-to-Q2 turnaround. Q2 FY27 pre-tax profit of Rs 17.19 crore was below Rs 19.37 crore in Q2 FY26, while profit after tax declined from Rs 14.48 crore to Rs 13.13 crore and earnings per share moved from Rs 1.06 to Rs 0.96.

Why did Systematix's H1 FY27 pre-tax profit fall?

Systematix's H1 FY27 pre-tax profit fell because the Rs 3.08 crore Q1 loss reduced the contribution from the profitable second quarter. Consolidated pre-tax profit was Rs 14.11 crore for the half year ended September 30, 2026, compared with Rs 33.24 crore in H1 FY26, a 57% reduction stated in the presentation.

The decline extended to profit after tax, which fell to Rs 8.24 crore in H1 FY27 from Rs 24.94 crore a year earlier. Half-year earnings per share were Rs 0.60 against Rs 1.83 in H1 FY26, while equity share capital remained Rs 13.65 crore in both periods.

Reported and adjusted income point in different directions for the half year. Reported total income from operations increased to Rs 114.07 crore from Rs 89.07 crore, whereas adjusted revenue declined to Rs 84.06 crore because the adjusted series treats share-trading revenue as its net profit or loss rather than gross revenue.

What did Systematix's Q2 revenue and margin show?

Systematix reported adjusted revenue from operations of Rs 56.04 crore in Q2 FY27, compared with Rs 55.72 crore in Q2 FY26 and Rs 28.02 crore in Q1 FY27. The presentation described the Q2 adjusted-revenue increase as 102% quarter on quarter and reported adjusted H1 FY27 revenue of Rs 84.06 crore.

The stated Q2 pre-tax margin was 29%, compared with 34% in Q2 FY26. The financial-highlights page pairs that 29% margin with pre-tax profit of Rs 17.18 crore, while the statutory consolidated results extract reports Rs 17.19 crore, a Rs 0.01 crore difference between the two presentation pages.

The source does not provide a segment-level revenue or expense breakdown for Q2 FY27. It does provide two revenue measures, including reported income of Rs 57.81 crore and adjusted revenue of Rs 56.04 crore, so comparisons need to use the same measure across periods.

How is Systematix investing in private wealth?

Systematix said it is making upfront investment in its private-wealth business through senior-talent acquisition, technology enablement and regulatory infrastructure. Management said those investments affected short-term profitability in Q2 FY27 and are expected to support sustainable revenue growth, which is management's stated expectation rather than a reported outcome.

The operating measures disclosed alongside that plan increased during the quarter. Total assets under management, or AUM, rose to Rs 1,151 crore in Q2 FY27 from Rs 910 crore in Q1 FY27, including mutual-fund AUM of Rs 803 crore, portfolio-management-services AUM of Rs 223 crore and alternative-investment-fund AUM of Rs 125 crore.

Private-client-group activity also expanded, with broking clients rising to 95 in Q2 FY27 from 73 in Q1 FY27 and broking AUM increasing to Rs 658 crore from Rs 520 crore. Assets under custody rose from Rs 10,800 crore to Rs 12,200 crore, while team strength increased from 25 to 38 and Systematix opened four offices in Mumbai, Indore, Kolkata and Delhi.

What asset-management milestones and pipeline did Systematix disclose?

Systematix disclosed that its Category I India SME Growth Fund had completed seven investments, drawn 65% of capital and exited its first investment. The fund had two portfolio companies listed and three portfolio companies that had filed draft red herring prospectuses, or DRHPs.

The Category II India Equity Opportunities Fund had investor interest or commitments of more than Rs 170 crore, against a targeted fund raise of Rs 750 crore to Rs 800 crore. Systematix also said its Category III India Select Equity Fund had received Securities and Exchange Board of India approval, while first tranches had been deployed in the Million to Billion and Systematix Emerging Leaders portfolio-management schemes.

Systematix listed a transaction pipeline of more than Rs 12,600 crore across more than 27 active opportunities. The largest identified item was a Rs 3,000 crore capital-goods qualified institutional placement opportunity; the pipeline represents prospective transactions rather than reported revenue or completed deals.

Conclusion

Systematix's results show a clear difference between the quarterly recovery and the first-half comparison. The company moved from a Rs 3.08 crore pre-tax loss in Q1 FY27 to Rs 17.19 crore of pre-tax profit in Q2, but H1 pre-tax profit of Rs 14.11 crore remained below Rs 33.24 crore in H1 FY26 as adjusted revenue fell 6% to Rs 84.06 crore.

The next measures to watch are execution of the private-wealth build, including the team increase to 38 people, and progress toward the Category II fund's Rs 750 crore to Rs 800 crore target. Systematix's disclosed pipeline of more than Rs 12,600 crore and 27 active opportunities will also require conversion into completed transactions before it can affect reported results.